Get started

PHARMA

OGEN Long into and past earnings! Starting Today!AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday. DD: OGEN has *1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15 Million worth of Warrants that will expire the day before. :) Also OGEN as obtained FDA Fast Track approval for this drug and marketing agreements completed in Europe to put it on the shelves immediately if Phase 2 data is good. *1 drug for lowering cholesterol by 70% currently in Phase 1trial, expect results and Ph2 announcement mid/early summer. *$21 Million cash on hand with burn rate of less than 10 Million per year. *This Monday OGEN bought a COVID19 trial drug company with 4,000,000 shares or roughly $1 Million. Trading in a channel, well established bases in this range over the last year or two, no need for extra funding for at least 1 year.
AMEX:OGENLong
by TheStockMarketSniper
1
Ahrvo Daily Movers: Horizon Therapeutics-Bullish on this BiotechAbout Horizon Therapeutics Horizon Therapeutics(ticker: HZNP) is a biopharmaceutical company that focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. HZNP was founded in 2005 and is headquartered in Dublin, Ireland. Ahrvo Stock Rankings Horizon Therapeutics is a top-ten ranked stock on Ahrvo, coming in 6th place (out of over 7,000+ stocks we cover) based on the most recent daily rankings. HZNP has an AhrvoScore (overall score) of 99. Over the last 3 months, Horizon has seen a slight increase in AhrvoScore, up 2 points. Momentum Score, Quality Score, Value Score, and Growth Score are top-notch, clocking in at 94, 80, 99, and 99, respectively. All four sub-scores have increased over the last 3 months. Momentum is up 5 points, Quality up 1 point, Value up 5 points, and Growth up 2 points. Furthermore, Horizon Therapeutics ranks higher than its competitors across all stock scores: Ahrvo Score 99 vs. 35, Momentum Score 94 vs. 62, Value Score 99 vs. 14, Quality Score 80 vs. 18, and Growth Score 99 vs. 42. Ahrvo’s proprietary trading signal also indicates that HZNP is currently a STRONG BUY. Our Take Horizon Therapeutics has performed well relative to the S&P 500 (ticker: SPY) and Nasdaq Biotechnology Index (ticker: IBB). Over the last 6 months, HZNP is up +21%, while the S&P 500 and Biotech Index have returned -8% and +10%, respectively. The company is extremely profitable with net margins of 44%. Last year they earned $573 million on $1.3 billion in revenue. Horizon Therapeutics reports Q1 earnings on Wednesday and is expected to beat analyst expectations. HZNP’s orphan drug portfolio should remain resilient and continue to perform well in the face of economic uncertainty. Orphan drugs are created for extremely rare diseases and drug recipients will need HZNP’s remedies irregardless of what happens with the broader economy. The analyst community is positive on the stock as well. Out of the 12 analysts that cover the company, 10 have HZNP rated as a strong buy (3) or buy (7), with 2 holds. Horizon Therapeutics 12-month median price target is $44.60, representing 25% upside from current levels. -Appo Agbamu, CFA This material is for informational purposes only. Under no circumstances should any information or materials presented be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. Any investment made is at your sole discretion. There are many factors that you must consider when making an investment decision, including, but not limited to, product features, risks, whether or not an investment meets your investment objectives, risk tolerance, and other personalized factors. Investing in securities involves risks, and there is always the potential of losing your entire investment.
HLong
by AhrvoStockApp
$TEVA - Weekly Chart 2020Teva's earnings May 7th - www.sec.gov Weekly chart is flashing buy signals with the 50SMA Crossing back under the price. Unknowns: COVID-19 impact on TEVA earnings Decision - Wait until after earnings to get in, still to many unknowns. The reason I like TEVA : Possible Turn-around play, looking for teva to turn net-loss to net-profit in the coming years if they continue to lower debt and start turning profit. Earnings (loss) per share attributable to ordinary shareholders: Basic ($) 2020 - Lower? 2019 - (0.91) even lower? 2018 - (2.35) Lower loss 2017 - (16.26) Huge loss 2016 - 0.07 Smaller profit 2015 - 1.84 Profit Diluted ($) 2019 - (0.91) 2018 - (2.35) 2017 - (16.26) 2016 - 0.07 2015 -1.82 www.sec.gov
NYSE:TEVALong
by AaronX
Easy Swing?GILD is moving with the news these days but the risk vs. reward is looking good, even after coming of the Double Top. I would love to see it bounce of the trend line and buy around $71 for a easy swing to an $80 target. Any good news can make this happen sooner than later. Regardless of the outcome of the trials, big pharma is one of the safest spots to invest right now in my opinion. Take this all with a grain of salt and do your own homework. I honestly have no idea what I'm talking about but just throwing up some ideas to look back at later.
NASDAQ:GILDLong
by lroman90
Another oversold pharma! Destiny Pharma (#DEST $DEST)See my chart for Oncimmune. Nice little bagger and similar conditions here. RSI just above 20. Historically, price has bounced when RSI has been between 12-20. Bought a tranche already and ready to buy more if it does slip further (possible depending on when/if results are released as that may let stale retail holders out). Price hovering on the lower BB bands so plenty of scope for recovery. Would have liked to seen the bands start narrowing but again another opportunity to buy more. Volume profile (weekly chart since IPO) about 44p. However, Phase 2B results due in H2, which, if successful, would be a major rerate catalyst and broker has a 250p target which is nice ramp fodder. Realistically, they'll need funding for Phase 3 (be it a placing or investment from a major). So happy to take a bag here and evaluate at the time whether to take a free ride or all the funds.
DLong
by AttilaTheKiller
NAVAMEDIC (NAVA) | Perfect Technically but Fundamentally So-So!Hi, Navamedic ASA, a MedTech and pharmaceutical company, in-licenses, buys and markets pharmaceuticals and other health care products in the Northern European region. Considering technical viewpoints then Navamedic has started to approach a pretty strong support area, a lot of criteria make up a strong crossing area. To be honest, I don't know much about Navamedic fundamentals but I can say, if you see some perspective in the future then this would be your perfect spot to buy it if you don't see then SKIP IT!! Technically a strong support area/buy-zone consists of: 1) A very strong resistance level becomes support. The price tried to break above the lower orange line 9(!) years and in the last year, it finally was successful. Now, this very strong resistance should act as a support level. 2) Inside the green buy-zone are also Monthly EMA50 and EMA100, plus Weekly EMA200 - all of them should act as support levels. 3) Fibonacci Golden ratio - Fibo retracement 62% 4) Navamedic becomes a member of a 50% club if the price reaches into the marked area. 5) Weekly timeframe AB=CD 6) Weekly timeframe channel projection It should be a pretty good spot to gain short-term profits, a perfect area should stay between 11.00-12.50 As said, do your own fundamental research and if this matching with my technical analysis viewpoints then you are ready to go! If it doesn't match then...skip it!! Regards, Vaido
OSL:NAVALong
by VaidoVeek
Speculative High-Return Idea - LONG "TEVA"I'm not gonna explain the fundamental data of the company for a long time, but I will say briefly that if you look at the dynamics of changes in the company's data, you can see a stable growth of the EPS indicators and a gradual moving towards a positive P&L. It is also indicative that with the huge fall of markets last week, the company did not “fly down” after the market. In the pharmaceutical sector, which itself is risky for investors, TEVA in recent months has shown good growth and the POTENTIAL for the long-term trend to transition from falling to rising. It has already broken up the resistance line lasting from the highest 2015 year point. However, the idea of ​​this post is no longer in long-term investment in this asset, but in speculative buying. The graph clearly shows the divergence of the asset price lows and its RSI and MACD indicators. According to Fibonacci, the stock adjusted to the desired level. Perhaps the fall to the level of 3703 Israeli Shekels and a rebound, or a rebound will be tomorrow. In any case, it is recommended to wait until the RSI fixes above 30 on the 1-hour chart, and then go into the idea. The way out of the idea is at least 4100 Shekels. Stop loss at your discretion, but 3650 is recommended. If you do not have access to the Israeli market, then do not be discouraged, paper is also listed in America under the same name TEVA P.S. It’s up to you to enter long-term or speculate, I recommend speculating only because I myself am a short-term speculator.
TASE:TEVALong
by Eminence-Grise
Pharma Stocks Don't move MuchWell for some reason the News is Killing the Market, I am down 60% Today, so decided to look at things with a different Light. Which ones Move differently depending on the Hype / News that is in our Ears. Got this one for $10 and next day it was $16 that might be the top for this one but Maybe not? I did not draw on the Chart but you can see it took off like a Rocket. There are Three Stocks that are dealing directly with Coronavirus this one was moderate price so I went with this guy. If it gets close to some of their previous levels could be interesting month. Just thought I would share. Have a good day and don't forget to Wash your Hands.
NASDAQ:NVAXShort
by Dudleydogg
3
CJJD On WatchChinese pharma play: - Move from 1.00 (May 24, '19) to recent $2.24 top (Jan 27, '20) and back to $1.73 today marks an approximate 50% retrace over the last 9 months - Currently in the heat of the Coronavirus battle; will likely show a bump in it's topline next quarterly report (July?) - Currently faces resistance at the baseline of the BB bands and 50MA which are both at $1.75 - Above its 200MA - 52 week high at $3.39 - Next stop is at $1.94 trendline, with support at $1.75 IF the price holds and is confirmed. - More support at 20MA ($1.71) and 9EMA ($1.67) - MACD looking ready for a crossover - KST at bottom of its range PT of $1.94 in the short term Back to $3.00 by July Stop Loss at $1.65 ------- Leave some feedback if you see things I can do better with my chart or if you have different ideas about what you see here in general! GLTA
NASDAQ:CJJDLong
by Blue_Collar_Trader